Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (169)	1/19/1999 3:20:00 PM
From: Scott H. Davis	Respond to of 613

Steve & Dude - RE: Genes and Hemophilia. Thought you'd be interest in this part of an IMNR release I read today. <<The Immune Response Corporation, a biopharmaceutical company based in Carlsbad, California, develops immune-based therapies to induce specific T cell responses for the treatment of HIV, autoimmune diseases, and cancer. The Company is conducting clinical trials on immune-based therapies for HIV, rheumatoid arthritis, psoriasis, multiple sclerosis, colon cancer and brain cancer, and preclinical studies for melanoma and prostate cancers. In addition, the Company is developing a delivery technology to enable intravenously-injected genes to target the liver. This gene therapy program includes preclinical studies for the treatment of hemophilia and hepatitis.